1.23

1.65% 0.02

After Hours: 1.24 0.01 +0.81%

Pliant Therapeutics Inc (PLRX)

Overview News Price History Option Chain Financials Discussions Forecast

Pliant Therapeutics Inc stock is traded at $1.23, with a volume of 561.87K. It is up +1.65% in the last 24 hours and down -6.11% over the past month. Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

Previous Close:

$1.21

Open:

$1.2

24h Volume:

561.87K

Relative Volume:

0.96

Market Cap:

$76.16M

Revenue:

$248.00K

Net Income/Loss:

$-149.34M

P/E Ratio:

-0.5052

EPS:

-2.4348

Net Cash Flow:

$-128.71M

1W Performance:

+1.65%

1M Performance:

-6.11%

6M Performance:

-19.61%

1Y Performance:

-13.99%

1-Day Range:

$1.20

$1.26

1-Week Range:

$1.19

$1.26

52-Week Range:

$1.09

$1.95

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name

Pliant Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

650-481-6770

Address

331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

PLRX's Discussions on Twitter

Compare PLRX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PLRX Pliant Therapeutics Inc	1.23	74.92M	248.00K	-149.34M	-128.71M	-2.4348
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-25	Downgrade	JP Morgan	Neutral → Underweight
Mar-04-25	Resumed	Cantor Fitzgerald	Neutral
Mar-04-25	Downgrade	Needham	Buy → Hold
Mar-03-25	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-03-25	Downgrade	Stifel	Buy → Hold
Feb-10-25	Downgrade	Canaccord Genuity	Buy → Hold
Feb-10-25	Downgrade	Citigroup	Buy → Neutral
Feb-10-25	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-10-25	Downgrade	JP Morgan	Overweight → Neutral
Feb-10-25	Downgrade	Oppenheimer	Outperform → Perform
Feb-10-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Feb-10-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-09-24	Resumed	Leerink Partners	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
May-18-23	Initiated	Canaccord Genuity	Buy
Apr-13-23	Initiated	Robert W. Baird	Outperform
Dec-14-22	Initiated	Stifel	Buy
Dec-07-22	Initiated	JP Morgan	Overweight
Sep-01-22	Initiated	Citigroup	Buy
Jul-20-22	Initiated	SVB Leerink	Outperform
May-25-22	Initiated	Cantor Fitzgerald	Overweight
Dec-10-21	Initiated	Oppenheimer	Outperform
Nov-24-21	Initiated	RBC Capital Mkts	Outperform
Nov-03-21	Initiated	H.C. Wainwright	Buy
Apr-20-21	Initiated	BTIG Research	Buy
Apr-05-21	Initiated	Citigroup	Buy
Jun-29-20	Initiated	Citigroup	Buy
Jun-29-20	Initiated	Cowen	Outperform
Jun-29-20	Initiated	Needham	Buy
Jun-29-20	Initiated	Piper Sandler	Overweight

View All

Pliant Therapeutics Inc Stock (PLRX) Latest News

08:42 AM

Pliant CEO, CFO to join RBC healthcare fireside chat on May 19 - Stock Titan

08:42 AM

08:30 AM

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference - GlobeNewswire

08:30 AM

May 04, 2026

PLRX SEC FilingsPliant Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

May 04, 2026

Pliant Therapeutics Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView

May 04, 2026

May 03, 2026

Pliant Therapeutics (NASDAQ:PLRX) Upgraded at Wall Street Zen - MarketBeat

May 03, 2026

Apr 30, 2026

Pliant Therapeutics (PLRX) Initiates Key Clinical Trial for Canc - GuruFocus

Apr 30, 2026

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors - Investing News Network

Apr 30, 2026

Pliant Therapeutics begins trial of cancer drug combination By Investing.com - Investing.com South Africa

Apr 30, 2026

Pliant Therapeutics begins trial of cancer drug combination - Investing.com

Apr 30, 2026

New cancer trial starts for patients after immunotherapy stops working - Stock Titan

Apr 30, 2026

Apr 27, 2026

Pliant Therapeutics (PLRX) price target decreased by 17.95% to 2.72 - MSN

Apr 27, 2026

Apr 25, 2026

Pliant Therapeutics Inc (FRA:9PT) Stock Price & 30 Year Financial Data - GuruFocus

Apr 25, 2026

Wall Street Zen Downgrades Pliant Therapeutics (NASDAQ:PLRX) to Sell - MarketBeat

Apr 25, 2026

Apr 22, 2026

Pliant Therapeutics (NASDAQ: PLRX) outlines 2026 virtual meeting, board changes and pay vote - Stock Titan

Apr 22, 2026

[ARS] PLIANT THERAPEUTICS, INC. SEC Filing - Stock Titan

Apr 22, 2026

Apr 21, 2026